Zopes

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zopes

Property Description
Active Ingredient Aciclovir (Acyclovir)
Form Tablet, Capsule, Suspension, IV Solution, Cream, Ointment
Pharmacological Class Selective Antiviral Agent
General Purpose Halts viral multiplication
Origin Synthetic Nucleoside Analogue

What Type of Medicine is Zopes (Aciclovir)?

Zopes is a medication containing the active ingredient Aciclovir (INN), which is precisely classified as a Selective Antiviral Agent. This synthetic compound is defined as a purine nucleoside analogue chemically related to the natural substance Guanosine. The medication is characterized by being a single-ingredient product, focusing entirely on the action of Aciclovir. Its foundational efficacy is established through its specific mechanism against viral enzymes and its critical role in health systems.

The medicine is manufactured in various pharmaceutical preparations to meet diverse clinical needs. These include oral forms (tablet, capsule, and oral suspension) for systemic treatment, an Intravenous (IV) Solution for parenteral administration in severe cases, and topical forms (Topical Cream and Ophthalmic Ointment) for localized treatment via the topical route.

Composition and General Purpose of Aciclovir

The core component is the chemically synthesized molecule Aciclovir (specifically 9-[(2-hydroxyethoxy)methyl]guanine), which is formulated into its final presentation using different bases or vehicles—such as a sterile aqueous solution or an emulsified cream base.

The established general purpose of this selective antiviral agent is to combat infection by directly interfering with the ability of specific viruses to reproduce themselves. Aciclovir is recognized for its targeted action; the mechanism involves the drug acting as a deceptive substrate, or nucleoside analogue, which is incorporated into the viral DNA to cause chain termination. The benefit of this targeted action is the limitation of the spread and progression of the underlying viral condition by halting viral multiplication.

What side effects are possible with Zopes?

Possible side effects and safety information

The medicine's safety profile is documented and classified by regulatory authorities based on the frequency and the System-Organ-Class (SOC) affected. This classification system organizes possible adverse reactions into categories, ranging from Very Common to Very Rare.

Official Adverse Reaction Categories

Classification Examples of Documented Effects
Common Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, fever, fatigue, pruritus, and rash.
Uncommon Urticaria and accelerated diffuse hair loss (alopecia).
Rare Acute renal failure, reversible increases in liver enzymes and bilirubin, Angioedema, and Anaphylaxis.
Very Rare Severe neurological reactions such as encephalopathy, convulsions, psychotic symptoms, hepatitis, and jaundice.

Serious adverse reactions are explicitly noted in regulatory documents and include Acute Renal Failure, Anaphylaxis, and Encephalopathy, which are highlighted due to their clinical significance. The dermatological effects, such as rash and pruritus, are categorized under Skin and Subcutaneous Tissue Disorders.

Safety Considerations for Specific Populations

Official labels address specific safety considerations for certain patient groups. Older adults and individuals with renal impairment are documented to have an increased risk of neurological adverse reactions due to potential drug accumulation. For intravenous (IV) administration, the regulatory information emphasizes the need for a slow infusion rate and adequate hydration as necessary restrictions to minimize the risk of renal toxicity, which is an exposure-related safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on the documented overdose findings and emergency requirements stated in government regulatory labeling.

Overdose Presentation Key Clinical Manifestations
Oral Overdose (Repeated) Gastrointestinal effects (nausea, vomiting); Neurological effects (headache, confusion).
Intravenous (IV) Overdose Acute Renal Failure (elevated serum creatinine, BUN, crystalluria); Severe CNS effects (agitation, seizures, coma, hallucinations).

Repeated accidental oral overexposure or over-infusion of the IV preparation are the documented overdose risks. Single oral ingestions of up to 20 g have been generally reported as non-toxic in regulatory literature. No specific antidote is known for Zopes overdose.

Emergency Actions Mandated by Authorities

Immediate medical help must be sought if the overdose victim has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. These signs require immediate contact with emergency services.

In the event of an overdose, patients must be observed closely for signs of toxicity. Management is specified as symptomatic and supportive treatment. Haemodialysis may be considered a management option for symptomatic overdose, as it significantly enhances drug removal.

Population-Specific Overdose Notes

Both elderly patients and those with impaired renal function are at a higher risk of developing documented neurological side effects due to reduced drug clearance. These neurological reactions are typically noted as reversible upon discontinuation.

Therapeutic Uses of Zopes

What Zopes Treats: Main Uses and Benefits

Zopes (Aciclovir) is commonly used to help manage symptoms related to heightened physiological activity caused by infections from the Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) families. In clinical use, this medication addresses conditions presenting with acute or disruptive episodes of viral replication.

This therapy is commonly used when groups of symptoms appear suddenly or fluctuate, and may assist with managing symptoms that interfere with daily comfort. It is relevant for easing challenging symptoms associated with both frequent manifestations like cold sores and episodes of genital herpes, as well as conditions caused by VZV, including the acute phase of shingles (Herpes Zoster).

Zopes is applied across therapeutic domains where additional symptomatic support is needed, primarily through suppressive therapy to reduce the number and severity of recurrent episodes. For immunocompromised individuals, it is applied in scenarios where additional management of discomfort is required, supporting general well-being during symptomatic phases.


Quick Fact: Relief for Acute Pain and Lesion Healing Zopes is applied in clinical settings that involve acute or unstable symptom patterns. It contributes to easing the overall symptom load by supporting the healing of lesions and helping to reduce the intensity of pain and discomfort during an active viral episode.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Zopes (Aciclovir) is defined by regulatory standards that specify who may use the medicine and under what conditions. The absolute non-eligibility rule applies to patients with a known hypersensitivity to aciclovir, valaciclovir, or any of the product's excipients. Furthermore, the oral suspension form is formally contraindicated in patients with hereditary fructose intolerance.

Population Restrictions

Use of Zopes is established for adults and children two years of age and older. However, restrictions apply to certain groups, necessitating conditional use or assessment:

  • Renal Function: The dose must be adjusted for all patients with impaired renal function due to the drug's primary clearance route. This consideration also applies to older adults, who are likely to have reduced renal clearance.
  • Pediatric Use: The safety and effectiveness of the topical cream formulation have not been established in children less than 12 years of age.
  • Pregnancy and Lactation: Use during pregnancy is permitted only when the potential benefits outweigh the unknown risks. Caution is also advised when administering Zopes to nursing women, as the substance is known to pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory data defines the primary pharmacokinetic mechanism of Zopes (Aciclovir) interactions as competition for active renal tubular secretion, the process by which the drug is eliminated unchanged from the body. Co-administration of medicines that also utilize this transporter pathway may reduce Aciclovir clearance, leading to documented increases in systemic exposure.


Specific Interacting Substances:

  • Probenecid and Cimetidine are documented to increase Aciclovir plasma concentration (Area Under the Curve or AUC) and decrease its renal clearance.
  • Mycophenolate Mofetil (MMF) co-administration formally increases the plasma AUCs of both Aciclovir and the MMF inactive metabolite.
  • Aciclovir co-administration may increase the plasma concentration of Theophylline, documented to raise its AUC by approximately 50%.
  • The use of Aciclovir alongside other nephrotoxic drugs is associated with an increased regulatory-documented risk of acute renal impairment.

Population-Specific Caution and Constraints:

This interaction profile is amplified in specific populations. Elderly patients and those with pre-existing renal impairment experience inherently reduced renal clearance, which results in higher systemic exposure and greater sensitivity to interaction effects that further compromise clearance. No drug-drug combinations are listed as formally contraindicated. Oral bioavailability is not significantly affected by food.

Mechanism of Action

Modulating Brain's Inhibitory Signals: The GABAA Receptor

Zopes acts as a positive allosteric modulator at the GABAA receptor complex in the central nervous system. This mechanism involves binding to a specific site on the receptor, which amplifies the natural inhibitory effect of the primary inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). The GABAA receptor is a ligand-gated ion channel; its increased activity enhances the influx of chloride ions into the postsynaptic neuron, leading to hyperpolarization and an increase in nerve cell inhibition.


Central Nervous System Slowdown and Decreased Arousal

This widespread amplification of inhibitory signaling across the brain causes a generalized slowing or depression of nerve activity. This systemic effect leads directly to the drug's core physiological consequences: skeletal muscle relaxation and a reduction in neural excitability via modulation of highly excitable neural pathways. This centralized action influences functional systems that regulate motor tone and arousal.

Dosage and Administration Information

How to Use Zopes (Aciclovir): Administration Guidelines

Zopes (Aciclovir) is used according to specific, indication-based protocols. The method of administration is governed by the required site of action, ranging from systemic exposure for severe conditions to localized therapy for surface infections. The administration can utilize multiple routes, including oral (tablet, capsule, or suspension), intravenous (IV) infusion, topical (cream or ophthalmic ointment), and buccal (delayed-release tablets).


Dosing and Frequency Patterns

The standard dosing is not uniform; it is indication-specific and defined by the regimen established for the medication. Acute systemic treatment often requires frequent dosing, such as 200 mg or 800 mg administered five times daily (approximately 4-hourly while awake) for durations like 5 to 10 days. Conversely, chronic suppressive therapy for recurrent conditions follows a less frequent schedule, typically 400 mg twice daily. Intravenous administration is reserved for severe infections and is generally given in 8-hour intervals, requiring a slow infusion over at least one hour to ensure proper delivery.

Administration Conditions and Adjustments

Standard instructions for use stipulate that oral forms may be taken with or without food. For proper use, patients must maintain adequate hydration, especially when receiving high-dose oral or IV therapy. A critical procedural constraint is the mandatory dose adjustment for individuals with reduced kidney function (renal impairment); the dose amount or frequency must be decreased to align with the body’s slower clearance rate. Furthermore, treatment for acute episodes must be initiated as early as possible—ideally within 72 hours of symptom onset—to adhere to the drug's use profile.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zopes (Aciclovir)

Evidence for Use in Acute Herpes Simplex Virus (HSV) Episodes

Studies have been conducted using short-term randomized controlled trials (RCTs) to explore the use of Zopes in people experiencing their first episode of genital herpes, as well as for the episodic treatment of subsequent recurrences. Research examined individuals with fluctuating or episodic manifestations of the condition. In these trials, researchers primarily monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. The findings describe patterns observed in the studies where the time measurements for lesion healing and symptom duration were reported to be lower in the groups that received Zopes compared to the control groups. Comparative evidence is also lacking when trying to evaluate this specific episodic use against all available newer therapeutic agents.

Evidence for Preventing Recurrent Genital Herpes

This research scenario involves long-term studies, including RCTs, where Zopes was evaluated in people with frequent recurrent episodes as a suppressive therapy. Research describes patterns where the annual frequency of recurrent episodes had lower counts in the observed populations while they were undergoing continuous treatment. Data also show patterns of lower frequency of asymptomatic viral shedding. The evidence is relevant to studies concerning the conditions characterized by fluctuating manifestations. The study structure is insufficient to determine the influence on the recurrence rate once continuous therapy has been discontinued.

Evidence for Use in Acute Shingles (Herpes Zoster)

Zopes was studied for the treatment of acute shingles using placebo-controlled RCTs, often involving older adults. Studies examined outcomes such as the time until lesions healed completely and the duration and intensity of acute pain. Studies reported how symptoms evolved, noting shorter time measurements for lesion healing and lower measurements for the duration of acute pain compared to control groups. The research also monitored patterns related to long-term nerve pain (Post-Herpetic Neuralgia or PHN). The main research limitation is that the findings were mixed across every single original trial, though pooled data from multiple studies were used to describe patterns related to the long-term pain outcome.

Evidence in Special Populations and Research Gaps

Research has explored the use of Zopes in specific populations, including immunocompromised individuals where conditions may be more severe. For severe manifestations, Zopes was studied via intravenous (IV) administration in hospitalized patients. Research describes group patterns related to how patients responded to IV treatment in severe contexts. The evidence landscape contributes to understanding symptom patterns, but several limitations exist. Data for certain groups, such as children and pregnant patients, remain insufficient, and specific subgroup findings are uncertain. Long-term effects are not fully established in all populations.

Frequently Asked Questions (FAQ)

Common questions about Zopes (FAQ)


Q: If I miss a time when I take Zopes, what am I supposed to do?

A: Official patient information states that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose should be skipped to maintain the correct regimen. Official directions advise against taking two doses at the same time.


Q: Is Zopes safe for older adults?

A: Official documents note that older adults are more likely to have reduced renal clearance, which is how the body removes the medicine. This potential change in clearance may be linked to an increased risk of certain neurological side effects due to drug accumulation. Dosage adjustment, as determined by a healthcare provider, may be necessary to align with the body's clearance rate.


Q: Can Zopes affect my ability to get pregnant or be used during pregnancy?

A: Regulatory information indicates that use during pregnancy is permitted only when a healthcare provider determines that the potential benefit outweighs any unknown risks. Specific regulatory documents addressing Zopes's effects on human fertility (the ability to get pregnant) are limited.


Q: Do official documents mention any research about Zopes and long-term use?

A: Studies have examined Zopes for long-term suppressive therapy, which involves continuous use for recurrent conditions. This research describes patterns of lower frequency of recurrent episodes in populations observed during continuous treatment, according to the official evidence review.


Q: Why is Zopes sometimes called a 'selective' medicine?

A: Zopes is officially classified as a Selective Antiviral Agent. It is called 'selective' because its mechanism of action is targeted to interfere only with the multiplication process of certain viruses, thereby limiting their spread and progression.


Q: Can Zopes interact with herbal supplements like St. John's Wort?

A: Official regulatory data for Zopes focuses on drug-drug interactions, particularly with prescription medicines that affect how the kidneys remove the medicine. There is no explicit interaction listed with herbal supplements like St. John's Wort in the formal regulatory interaction sections.


Q: Why do doctors need to know my complete medical history before prescribing Zopes?

A: Official documents outline several factors that affect the use of Zopes, including renal (kidney) function, the risk of hypersensitivity, and considerations for older adults. A complete health profile supports the determination of appropriate use conditions and helps identify factors that may require dose adjustment.


Q: Does the time of day I take Zopes matter?

A: The time of day can matter, as regulatory instructions for acute treatment regimens usually require frequent dosing (e.g., five times daily). This frequency means doses are spaced evenly throughout waking hours, which is important for maintaining adequate levels of the medicine, consistent with the expected use.


Q: Does Zopes have warnings about sun exposure?

A: Some authoritative patient information indicates that Zopes may cause the skin to be more sensitive to sunlight, which could increase the risk of sunburn. Regulatory information indicates protective measures against sun exposure are sometimes recommended.


Q: Is Zopes a medicine that cures the condition or manages the symptoms?

A: Official sources describe Zopes as a medicine that helps manage the symptoms and severity of viral episodes by halting viral multiplication. Regulatory documents indicate that the medicine is not a cure, and the underlying virus remains in the body.


Q: Can Zopes be used for things besides the main condition it treats?

A: Regulatory bodies have authorized Zopes for multiple specific conditions caused by the herpes group of viruses. These conditions include initial and recurrent genital herpes, acute shingles (Herpes Zoster), and chickenpox.


Q: Are there any common over-the-counter medicines that interact with Zopes?

A: Official interaction profiles note a minor theoretical risk of increased Zopes plasma levels when taken with certain common non-steroidal anti-inflammatory drugs (NSAIDs). This is because some NSAIDs share the same pathway used for renal clearance (kidney removal) of Zopes.


Q: Why do some people feel sleepy when taking Zopes?

A: Drowsiness, fatigue, and dizziness are documented in official safety information as possible side effects. The central nervous system (CNS) effects that cause these reactions are listed among the possible adverse reactions for Zopes.


Q: Is Zopes considered a long-term medication?

A: Zopes is authorized for use in both short-term acute treatment regimens and as a chronic suppressive therapy for recurrent conditions. This suppressive use can involve continuous administration for periods of up to 12 months or longer, as documented in official labeling.


Q: What happens if I stop taking Zopes suddenly?

A: Official labeling instructs patients to continue using the medicine for the full time of treatment as ordered, even if symptoms begin to improve. Official labeling states that stopping the medicine before the full course is completed may be associated with a reduction in treatment efficacy.


Q: Can I take Zopes if I have a liver condition?

A: Although the liver is not the primary route of elimination, official labeling lists very rare adverse reactions such as reversible increases in liver enzymes, hepatitis, and jaundice. This indicates the need for monitoring and caution in some patients with pre-existing liver conditions.


Q: Does Zopes affect driving or operating machinery?

A: Regulatory information advises that any potential adverse event profile of Zopes, such as dizziness or headache, should be considered when assessing the ability to drive or operate machinery safely. The assessment of fitness to drive or operate machinery should consider individual health status and response to the medicine.


Q: What is the official classification of Zopes (e.g., Schedule IV)?

A: Zopes is officially classified as a prescription-only medicine (Rx) in most regulatory regions. It is not listed as a controlled substance (such as a Schedule I-V drug) by the U.S. FDA.


Q: Is it normal to have mild stomach upset when starting Zopes?

A: Gastrointestinal effects are included in the official safety profile. Effects such as nausea, vomiting, diarrhea, and abdominal pain are listed in regulatory documents as common side effects.


Q: How long does Zopes stay in the body after the last time it's taken?

A: Pharmacokinetic data available in regulatory documents indicate the elimination half-life of Zopes is generally described as being approximately two to four hours for patients with normal kidney function.


Q: Is there a generic version of Zopes available?

A: Regulatory records and authorized drug databases indicate that a generic version of Zopes, containing the active ingredient Aciclovir, is available in multiple dosage forms.


Q: Is Zopes addictive or habit-forming?

A: Zopes is not listed as a controlled substance by the FDA, and official regulatory documentation does not include warnings regarding physical dependence or addiction potential.


Q: Can Zopes be crushed or cut in half?

A: Regulatory labeling specifies that oral tablets should generally be swallowed whole with water. This procedure is described in the official instructions unless a scored, dispersible, or suspension form is specifically authorized.


Q: Does Zopes interact with alcohol?

A: There is no absolute prohibition or strict contraindication regarding alcohol in the official regulatory documents. Official documentation mentions that the potential for increased dehydration or exacerbation of side effects, such as dizziness, should be considered.


Q: Are there specific symptoms that signal a serious reaction to Zopes?

A: Official documentation highlights serious reactions such as anaphylaxis (a severe allergic reaction). Symptoms of anaphylaxis may include swelling of the face, tongue, or throat, and difficulty breathing. These types of reactions are considered clinically significant and require prompt assessment.


Q: Can Zopes cause changes in mood or behavior?

A: Very rare adverse reactions listed in regulatory documents include severe neurological effects such as confusion, hallucinations, and psychotic symptoms. These types of reactions relate to mood and behavior changes.


Q: Do I need regular blood tests while taking Zopes?

A: Official patient monitoring considerations may include checking certain health parameters, such as kidney or liver function. This is typically done, especially when Zopes is taken long-term or at high doses.

How should Zopes be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Zopes must adhere strictly to regulatory labeling to maintain potency and stability. The medicine is required to be stored at Controlled Room Temperature, typically defined as below 25 C or 30 C, and must be explicitly protected from freezing. To preserve the product, the container must be kept tightly closed in its original packaging to shield the contents from both light and moisture.

After any reconstitution or first opening, the official label defines a limited in-use stability period, after which any remaining portion must be discarded. To ensure child safety, Zopes must always be stored out of the sight and reach of children.

Disposal of Unused Medicine

Official disposal instructions prohibit flushing Zopes down the toilet or pouring it into a drain. Unused, expired, or contaminated product must be disposed of through a government-authorized drug take-back program or a licensed pharmaceutical waste collector, following all local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zopes found in:

A-Z Index: